LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

Home・Akciju saraksts・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Slēgts

4.1 10.51

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.58

Max

4.1

Galvenie mērījumi
By Trading Economics
Ienākumi	-136K -35M
Darbinieki	106
EBITDA	-619K -38M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+97.74% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 4. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-36M 258M
Iepriekšējā atvēršanas cena	-6.41
Iepriekšējā slēgšanas cena	4.1

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

1.23 / 1.45 Atbalsts un pretestība

Zentalis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 21. maijs 22:48 UTC

Iegādes, apvienošanās, pārņemšana

Conduent to Sell Public Transit Business to Modaxo for $164 Million

2026. g. 21. maijs 16:49 UTC

Peļņas

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

2026. g. 21. maijs 16:26 UTC

Galvenie tirgus virzītāji

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

2026. g. 21. maijs 23:51 UTC

Tirgus saruna

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

2026. g. 21. maijs 23:37 UTC

Peļņas

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

2026. g. 21. maijs 23:37 UTC

Peļņas

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

2026. g. 21. maijs 23:37 UTC

Peļņas

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

2026. g. 21. maijs 23:34 UTC

Tirgus saruna

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

2026. g. 21. maijs 23:30 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 21. maijs 23:30 UTC

Tirgus saruna

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

2026. g. 21. maijs 22:33 UTC

Iegādes, apvienošanās, pārņemšana

Conduent to Sell Public Transit Business to Modaxo for $164M

2026. g. 21. maijs 21:53 UTC

Peļņas

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

2026. g. 21. maijs 21:02 UTC

Peļņas

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

2026. g. 21. maijs 20:55 UTC

Peļņas

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

2026. g. 21. maijs 20:30 UTC

Karstas akcijas

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

2026. g. 21. maijs 20:20 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 21. maijs 20:20 UTC

Tirgus saruna

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

2026. g. 21. maijs 20:20 UTC

Peļņas

Webull 1Q Adj EPS 3c >BULL

2026. g. 21. maijs 20:20 UTC

Peļņas

Webull 1Q Rev $159.9M >BULL

2026. g. 21. maijs 20:18 UTC

Tirgus saruna

Mexico's Inflation Seen Easing in Early May -- Market Talk

2026. g. 21. maijs 20:18 UTC

Peļņas

Webull 1Q Loss/Shr 4c

2026. g. 21. maijs 19:43 UTC

Tirgus saruna

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

2026. g. 21. maijs 19:33 UTC

Tirgus saruna

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

2026. g. 21. maijs 18:58 UTC

Peļņas

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

2026. g. 21. maijs 18:15 UTC

Tirgus saruna

Gold Higher For Second Consecutive Day -- Market Talk

2026. g. 21. maijs 17:40 UTC

Tirgus saruna

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

2026. g. 21. maijs 17:04 UTC

Tirgus saruna

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

2026. g. 21. maijs 17:01 UTC

Peļņas

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

2026. g. 21. maijs 16:20 UTC

Tirgus saruna

Peļņas

Stellantis Targets Distant but Constructive -- Market Talk

2026. g. 21. maijs 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Zentalis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

97.74% augšup

Prognoze 12 mēnešiem

Vidējais 7 USD 97.74%

Augstākais 10 USD

Zemākais 4 USD

Pamatojoties uz 7 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

7 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 7 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

1.23 / 1.45Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

There is one bearish event.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.